BioLargo: Five platforms, one subsidiary worth the entire parent.

Executive Summary

BioLargo, Inc. (OTCQX: BLGO) is a Westminster, California–based cleantech and life-sciences company organized around what management calls a single innovation engine — a shared base of electrochemistry and chemical-engineering competency — that produces five operating outputs: Clyra Medical (FDA-cleared wound care); BEST (PFAS removal); BLEST (engineering services and IP development); CupriDyne (industrial odor control); and Cellinity (pre-commercial liquid-sodium battery technology).

The company's April 2026 investor deck, marked "DRAFT — For discussion purposes," frames the central thesis bluntly: the value of BioLargo's roughly 48% equity stake plus 6% royalty in Clyra Medical, validated by a $20 million institutional financing implying a $100 million subsidiary valuation, is by itself comparable to the parent company's current market capitalization — meaning the other four operating units are, in management's framing, embedded at or near zero.

That framing is the investment case. The execution work — the work that determines whether the framing translates into recurring revenue — is what the next twelve months will reveal.

Business Overview

BioLargo's organizational logic is unusual for a small-cap cleantech company. Rather than concentrate on a single product line, the parent operates as both an intellectual-property holder and a holding company, licensing foundational technology to five operating subsidiaries that pursue field-of-use applications.

Clyra Medical — Wound Care (Commercial, FDA-Cleared)

Clyra is the most commercially advanced subsidiary. Its lead product, ViaCLYR, is a 510(k)-cleared antimicrobial wound-care product built on a patented copper-iodine chemistry described by the company as broad-spectrum against more than 19 pathogens — including MRSA, Pseudomonas aeruginosa, Klebsiella, E. coli, and Candida auris — with sustained activity up to three days even under re-contamination. The mechanism does not drive antimicrobial resistance and is tissue-compatible, distinguishing it from chlorhexidine and povidone-iodine alternatives.

Clyra holds two contracted distribution partners; a first commercial stocking order was received from Advanced Solution Wound Care on February 9, 2026, characterized by the company as Clyra's transition from development-stage to early commercial revenue. BLGO holds approximately 48% equity in Clyra plus a 6% royalty on Clyra's gross sales.

BEST — PFAS Removal (Commercial, First Municipal Install)

BEST operates the patented Aqueous Electrostatic Concentrator (AEC) — a turn-key system for water utilities designed to remove long-, short-, and ultra-short-chain PFAS to non-detect levels per EPA Method 1633 limits. Company test results for an industrial groundwater well show greater than 99% removal of PFPeA and PFOA, with all five tested PFAS species reduced to non-detect.

The first municipal commercial installation was completed on January 27, 2026 at the Lake Stockholm water facility in New Jersey, operating under a 12-month monitoring phase in collaboration with state regulators. A non-exclusive memorandum of understanding with global water-treatment firm Aquatech was announced on May 4, 2026 to integrate the AEC into Aquatech's worldwide PFAS treatment flowsheets.

BLEST — Engineering Services (Profitable, IP Front Door)

BLEST operates as a third-party engineering services business — and as the commercial front door for BioLargo's patented intellectual property. The company reports 98% year-over-year revenue growth in this unit for 2025. In April 2026, BLEST was awarded a $1.2 million pilot-design contract for a magnesium-recovery project at a Western U.S. legacy-tailings site, anchored on U.S. Patent 11,634,337 B2 (granted April 25, 2023). The structure gives BLEST a 10% net-operating-income share in perpetuity in exchange for a royalty-free technology license, with capital provided by Far West Industries — no BioLargo shareholder dilution is required for project CapEx.

CupriDyne — Industrial Odor and VOC Control (Repositioning)

CupriDyne is BioLargo's most mature technology and was historically its largest revenue contributor. Peak performance, per the deck, was approximately $6 million in net cash flow on $14 million in sales. The consumer arrangement with the Pooph brand was terminated, with the company filing litigation alleging formula substitution and patent infringement. The industrial sales base — for landfills, transfer stations, compost facilities, and wastewater plants — continues; new consumer-channel partnerships are being organized.

Cellinity — Liquid Sodium Battery (Pre-Commercial)

Cellinity is the most forward-looking and the largest stated optionality in the portfolio. The company markets a sealed liquid-sodium battery with cited specifications of greater than 500 Wh/kg energy density, approximately 95% round-trip efficiency, no thermal-runaway risk, and no lithium or rare-earth content. Target applications include AI data-center backup, grid-scale storage, EV fast-charging, and critical infrastructure. The company is pursuing a joint-venture or SPV financing strategy at the project level. Cellinity remains pre-revenue.

Recent Financial Performance

BioLargo reported full-year 2025 revenue of $7.765 million, down from $17.779 million in 2024, with a net loss of $15.189 million. The decline largely reflects the unwinding of the Pooph consumer relationship within CupriDyne; underneath the consolidated decline, BLEST's third-party engineering revenue grew 98% year over year, and Clyra began generating first commercial orders. The company ended 2025 with $3.883 million in cash and $8.311 million in total assets against $6.785 million in total liabilities.

Item	FY 2025	FY 2024	YoY
Revenue	$7.77M	$17.78M	-56.3%
Net Loss	$15.19M	—	—
Year-end Cash	$3.88M	—	—
Total Assets	$8.31M	—	—
Total Liabilities	$6.79M	—	—
BLEST Revenue Growth	+98%	—	—

Capital Structure and Market Data

BLGO trades on the OTCQX under the symbol BLGO. The stock closed at $0.15 on May 8, 2026, per Yahoo Finance, near the lower end of a 52-week range that Investing.com identified as approximately $0.14 to $0.30. Market-capitalization estimates across third-party data aggregators vary substantially — Stock Titan-adjacent sources cite figures near $10 million; Fintel cited approximately $82.5 million as of March 25, 2026 — a spread that reflects vendor-level differences in share-count handling rather than disagreement about the underlying float.

Capital-raising activity has occurred primarily at the subsidiary level. Clyra raised $20 million from institutional investors at an implied $100 million subsidiary valuation; Cellinity has raised approximately $5 million in outside capital. Per the deck, total outside investment across the platform — parent and subsidiaries combined — is approximately $50 million, with the parent itself having contributed roughly $25 million over the company's history.

Recent Developments

• January 27, 2026 — BEST installed AEC PFAS-removal system at Lake Stockholm, New Jersey, marking first municipal commercial deployment.
• February 9, 2026 — Clyra Medical secured first commercial stocking order from Advanced Solution Wound Care for ViaCLYR.
• April 2026 — BLEST awarded $1.2 million design-phase minerals contract for legacy-tailings magnesium recovery, anchored on U.S. Patent 11,634,337 B2.
• April 25, 2026 — Clyra signed exclusive distribution agreement with Al Hikma for the Middle East and North Africa region.
• May 4, 2026 — Non-exclusive memorandum of understanding signed with Aquatech, a global water-treatment firm, to advance commercialization of AEC for PFAS treatment worldwide.

Stated Investment Thesis

BioLargo's central argument, as presented in the deck, is structural: the parent's market capitalization reflects only the Clyra equity-and-royalty stake, with four other operating units embedded at or near zero. The argument is supported by a single private financing reference — the $20 million raised by Clyra at the subsidiary level implying $100 million for that one business.

The deck identifies a sequence of "turning point milestones" for each operating unit. For Clyra: a major distributor disclosure leading to launch at scale in a $20 billion wound-care market. For BEST: conversion of bidding activity into first executed wins under the Aquatech relationship, supported by EPA compliance deadlines through 2029 and settlement capital flowing from PFAS-manufacturer litigation. For BLEST: progression of the minerals project from design phase to pilot phase to full production. For CupriDyne: industrial stability plus a consumer relaunch plus litigation recovery, framed as three independent value paths. For Cellinity: securing an equity sponsor at the project level.

Investors weighing the thesis should note the explicit "DRAFT — For discussion purposes" labeling on the deck. That label limits the weight that should be placed on specific projections within.

Risks

• Revenue compression. 2025 consolidated revenue declined materially to $7.77 million from $17.78 million the prior year due to the CupriDyne / Pooph wind-down. Recovery depends on successor industrial sales and pending litigation outcomes.
• Subsidiary valuation reference. The $100 million implied Clyra valuation rests on a single private financing round, not a public-market reference. A sum-of-the-parts thesis tied to that mark is sensitive to subsequent rounds being executed at the same or higher valuation.
• Liquidity. Year-end 2025 cash of $3.88 million against ongoing operating losses raises continuing capital-needs questions. Subsidiary-level capital and parent-level placements have been recurring sources of funding.
• Pre-commercial exposure. Cellinity is pre-revenue and is described by management as actively seeking an equity sponsor.
• OTCQX trading venue. Liquidity, institutional participation, and analyst coverage are structurally constrained relative to senior exchanges.
• "DRAFT" deck disclosure. The April 2026 investor deck is marked "For discussion purposes — DRAFT," limiting the weight that should be placed on specific operating or valuation projections within.
• Litigation outcome. The Pooph litigation alleges formula substitution and patent infringement. Outcome timing and recovery quantum are not within company control.

Conclusion

BioLargo is a company whose narrative is built on a structural argument — that a multi-platform innovation engine, partially monetized through subsidiary equity and royalty positions, is being valued by the public market as if four of its five operating units do not exist. The argument has internal logic. Whether it converts to a re-rate depends on events that are scheduled but not yet delivered: a major Clyra distributor disclosure, Aquatech-supported PFAS deployment wins, progression of the BLEST minerals project from design to pilot, and a Cellinity equity sponsor. Each of those is a discrete, observable milestone — and each, if delivered, would furnish a concrete data point that investors could use to update against the deck's framing.

Until those events occur, the most useful investor posture is to monitor the catalyst calendar, weight delivered milestones over deck commentary, and treat the $100 million Clyra reference as one data point among several rather than a settled valuation.

Key Takeaways

• BioLargo operates five subsidiaries — Clyra (wound care), BEST (PFAS), BLEST (engineering), CupriDyne (odor control), and Cellinity (battery) — under a shared electrochemistry platform.
• Parent holds approximately 48% equity and a 6% royalty in Clyra Medical; the subsidiary's $20 million institutional financing implies a $100 million subsidiary valuation.
• FY2025 revenue declined to $7.77 million from $17.78 million the prior year. Year-end cash was $3.88 million.
• Near-term catalysts include further Clyra distributor disclosures, Aquatech-supported PFAS deployment wins, BLEST minerals project progression, and Cellinity equity-sponsor selection.
• The April 2026 investor deck is explicitly labeled "DRAFT — For discussion purposes."

Sources: BioLargo, Inc. — "Innovation Engine" investor deck dated April 2026 (marked DRAFT); BioLargo Form 8-K filings (SEC.gov, EDGAR accession 0000880242); GlobeNewswire and biolargo.com press releases (January–May 2026); Streetwise Reports; Value the Markets; Stock Titan; Yahoo Finance; CNBC; Investing.com; Fintel; Seeking Alpha.